The Influence of Parasympatholytics on the Resolution of Acute Attacks of Asthma
PURPOSE: To evaluate the role of parasympatholytics in the resolution of acute attacks of asthma. METHODS: This study employed a prospective sequential design in which the influence of 0.5 and 1.0 mg of ipratropium bromide on peak expiratory flow rates (PEFR), hospital admissions, and length of stay...
Gespeichert in:
| Veröffentlicht in: | The American journal of medicine 1997-01, Vol.102 (1), p.7-13 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 13 |
|---|---|
| container_issue | 1 |
| container_start_page | 7 |
| container_title | The American journal of medicine |
| container_volume | 102 |
| creator | McFadden, E.R. ElSanadi, Nabil Strauss, Louise Galan, Gayle Dixon, Lisa McFadden, Christopher B. Shoemaker, Laura Gilbert, Ileen Warren, Edward Hammonds, Terry |
| description | PURPOSE: To evaluate the role of parasympatholytics in the resolution of acute attacks of asthma.
METHODS: This study employed a prospective sequential design in which the influence of 0.5 and 1.0 mg of ipratropium bromide on peak expiratory flow rates (PEFR), hospital admissions, and length of stay (LOS) in the emergency department (ED) was evaluated. The parasympatholytic was added to a well-investigated standard therapeutic regimen that was anchored by the use of repetitive doses of albuterol, and employed pretested decision algorithms.
RESULTS: One hundred and thirty-one patients received ipratropium (I) and 123 who did not (NI) served as controls. There were no significant pretreatment between group differences in gender, racial composition, clinical signs and symptoms, or PEFR. The presence of ipratropium in the regimen did not influence discharge/admission patterns, LOS, the rate of improvement of the patients, or the level of PEFR achieved.
CONCLUSION: Anticholinergic agents such as ipratropium are not first-line treatments for acute asthma. They do not add any therapeutic benefit to the effects of albuterol given in divided doses over 1 hour, nor do they facilitate recovery in patients whose immediate response to sympathomimetics is impaired. |
| doi_str_mv | 10.1016/S0002-9343(96)00354-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79100137</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002934396003543</els_id><sourcerecordid>20861748</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-afdfaac499722ebcb417fea39eb712338f52ee8625fdb24919349411b9986dc43</originalsourceid><addsrcrecordid>eNqFkU1LJDEQhsPiorPu_gShERH30Lv57O6cZBB3FYSVVc8hna4w0e7OmKSF-fdmPpiDF0-hUk8VL08hdELwL4JJ9fsBY0xLyTi7kNVPjJngJfuCZkQIUdakogdotkeO0LcYn3OJpagO0aGkWBIpZuj-cQHF7Wj7CUYDhbfFvQ46roalTgvfr5IzsfBjkTL2H6Lvp-Rymbm5mRIU85S0eYmbj5gWg_6OvlrdR_ixe4_R05_rx6ub8u7f39ur-V1peENTqW1ntTZcyppSaE3LSW1BMwltTShjjRUUoKmosF1LeQ7LuOSEtFI2VWc4O0bn273L4F8niEkNLhroez2Cn6KqJcGYsDqDpx_AZz-FMWdTlFEmBJVrSGwhE3yMAaxaBjfosFIEq7VutdGt1i6VrNRGt2J57mS3fGoH6PZTO7-5f7br62h0b4MejYt7jIqaNJJm7HKLQTb25iCoaNz6IJ0LYJLqvPskyDtdXZrD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>232355297</pqid></control><display><type>article</type><title>The Influence of Parasympatholytics on the Resolution of Acute Attacks of Asthma</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>McFadden, E.R. ; ElSanadi, Nabil ; Strauss, Louise ; Galan, Gayle ; Dixon, Lisa ; McFadden, Christopher B. ; Shoemaker, Laura ; Gilbert, Ileen ; Warren, Edward ; Hammonds, Terry</creator><creatorcontrib>McFadden, E.R. ; ElSanadi, Nabil ; Strauss, Louise ; Galan, Gayle ; Dixon, Lisa ; McFadden, Christopher B. ; Shoemaker, Laura ; Gilbert, Ileen ; Warren, Edward ; Hammonds, Terry</creatorcontrib><description>PURPOSE: To evaluate the role of parasympatholytics in the resolution of acute attacks of asthma.
METHODS: This study employed a prospective sequential design in which the influence of 0.5 and 1.0 mg of ipratropium bromide on peak expiratory flow rates (PEFR), hospital admissions, and length of stay (LOS) in the emergency department (ED) was evaluated. The parasympatholytic was added to a well-investigated standard therapeutic regimen that was anchored by the use of repetitive doses of albuterol, and employed pretested decision algorithms.
RESULTS: One hundred and thirty-one patients received ipratropium (I) and 123 who did not (NI) served as controls. There were no significant pretreatment between group differences in gender, racial composition, clinical signs and symptoms, or PEFR. The presence of ipratropium in the regimen did not influence discharge/admission patterns, LOS, the rate of improvement of the patients, or the level of PEFR achieved.
CONCLUSION: Anticholinergic agents such as ipratropium are not first-line treatments for acute asthma. They do not add any therapeutic benefit to the effects of albuterol given in divided doses over 1 hour, nor do they facilitate recovery in patients whose immediate response to sympathomimetics is impaired.</description><identifier>ISSN: 0002-9343</identifier><identifier>EISSN: 1555-7162</identifier><identifier>DOI: 10.1016/S0002-9343(96)00354-3</identifier><identifier>PMID: 9209195</identifier><identifier>CODEN: AJMEAZ</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Acute Disease ; Adult ; Albuterol - therapeutic use ; Asthma ; Asthma - drug therapy ; Asthma - physiopathology ; Biological and medical sciences ; Bronchodilator Agents - therapeutic use ; Drug therapy ; Female ; Hospitalization ; Humans ; Ipratropium - therapeutic use ; Length of Stay ; Male ; Medical research ; Medical sciences ; Parasympatholytics - therapeutic use ; Peak Expiratory Flow Rate - drug effects ; Pharmacology. Drug treatments ; Respiratory system ; Treatment Outcome</subject><ispartof>The American journal of medicine, 1997-01, Vol.102 (1), p.7-13</ispartof><rights>1997 Elsevier Science Inc.</rights><rights>1997 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Jan 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c482t-afdfaac499722ebcb417fea39eb712338f52ee8625fdb24919349411b9986dc43</citedby><cites>FETCH-LOGICAL-c482t-afdfaac499722ebcb417fea39eb712338f52ee8625fdb24919349411b9986dc43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0002-9343(96)00354-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,4024,27923,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2571892$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9209195$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McFadden, E.R.</creatorcontrib><creatorcontrib>ElSanadi, Nabil</creatorcontrib><creatorcontrib>Strauss, Louise</creatorcontrib><creatorcontrib>Galan, Gayle</creatorcontrib><creatorcontrib>Dixon, Lisa</creatorcontrib><creatorcontrib>McFadden, Christopher B.</creatorcontrib><creatorcontrib>Shoemaker, Laura</creatorcontrib><creatorcontrib>Gilbert, Ileen</creatorcontrib><creatorcontrib>Warren, Edward</creatorcontrib><creatorcontrib>Hammonds, Terry</creatorcontrib><title>The Influence of Parasympatholytics on the Resolution of Acute Attacks of Asthma</title><title>The American journal of medicine</title><addtitle>Am J Med</addtitle><description>PURPOSE: To evaluate the role of parasympatholytics in the resolution of acute attacks of asthma.
METHODS: This study employed a prospective sequential design in which the influence of 0.5 and 1.0 mg of ipratropium bromide on peak expiratory flow rates (PEFR), hospital admissions, and length of stay (LOS) in the emergency department (ED) was evaluated. The parasympatholytic was added to a well-investigated standard therapeutic regimen that was anchored by the use of repetitive doses of albuterol, and employed pretested decision algorithms.
RESULTS: One hundred and thirty-one patients received ipratropium (I) and 123 who did not (NI) served as controls. There were no significant pretreatment between group differences in gender, racial composition, clinical signs and symptoms, or PEFR. The presence of ipratropium in the regimen did not influence discharge/admission patterns, LOS, the rate of improvement of the patients, or the level of PEFR achieved.
CONCLUSION: Anticholinergic agents such as ipratropium are not first-line treatments for acute asthma. They do not add any therapeutic benefit to the effects of albuterol given in divided doses over 1 hour, nor do they facilitate recovery in patients whose immediate response to sympathomimetics is impaired.</description><subject>Acute Disease</subject><subject>Adult</subject><subject>Albuterol - therapeutic use</subject><subject>Asthma</subject><subject>Asthma - drug therapy</subject><subject>Asthma - physiopathology</subject><subject>Biological and medical sciences</subject><subject>Bronchodilator Agents - therapeutic use</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Ipratropium - therapeutic use</subject><subject>Length of Stay</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Parasympatholytics - therapeutic use</subject><subject>Peak Expiratory Flow Rate - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Respiratory system</subject><subject>Treatment Outcome</subject><issn>0002-9343</issn><issn>1555-7162</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1LJDEQhsPiorPu_gShERH30Lv57O6cZBB3FYSVVc8hna4w0e7OmKSF-fdmPpiDF0-hUk8VL08hdELwL4JJ9fsBY0xLyTi7kNVPjJngJfuCZkQIUdakogdotkeO0LcYn3OJpagO0aGkWBIpZuj-cQHF7Wj7CUYDhbfFvQ46roalTgvfr5IzsfBjkTL2H6Lvp-Rymbm5mRIU85S0eYmbj5gWg_6OvlrdR_ixe4_R05_rx6ub8u7f39ur-V1peENTqW1ntTZcyppSaE3LSW1BMwltTShjjRUUoKmosF1LeQ7LuOSEtFI2VWc4O0bn273L4F8niEkNLhroez2Cn6KqJcGYsDqDpx_AZz-FMWdTlFEmBJVrSGwhE3yMAaxaBjfosFIEq7VutdGt1i6VrNRGt2J57mS3fGoH6PZTO7-5f7br62h0b4MejYt7jIqaNJJm7HKLQTb25iCoaNz6IJ0LYJLqvPskyDtdXZrD</recordid><startdate>199701</startdate><enddate>199701</enddate><creator>McFadden, E.R.</creator><creator>ElSanadi, Nabil</creator><creator>Strauss, Louise</creator><creator>Galan, Gayle</creator><creator>Dixon, Lisa</creator><creator>McFadden, Christopher B.</creator><creator>Shoemaker, Laura</creator><creator>Gilbert, Ileen</creator><creator>Warren, Edward</creator><creator>Hammonds, Terry</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Sequoia S.A</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>199701</creationdate><title>The Influence of Parasympatholytics on the Resolution of Acute Attacks of Asthma</title><author>McFadden, E.R. ; ElSanadi, Nabil ; Strauss, Louise ; Galan, Gayle ; Dixon, Lisa ; McFadden, Christopher B. ; Shoemaker, Laura ; Gilbert, Ileen ; Warren, Edward ; Hammonds, Terry</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-afdfaac499722ebcb417fea39eb712338f52ee8625fdb24919349411b9986dc43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Acute Disease</topic><topic>Adult</topic><topic>Albuterol - therapeutic use</topic><topic>Asthma</topic><topic>Asthma - drug therapy</topic><topic>Asthma - physiopathology</topic><topic>Biological and medical sciences</topic><topic>Bronchodilator Agents - therapeutic use</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Ipratropium - therapeutic use</topic><topic>Length of Stay</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Parasympatholytics - therapeutic use</topic><topic>Peak Expiratory Flow Rate - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Respiratory system</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McFadden, E.R.</creatorcontrib><creatorcontrib>ElSanadi, Nabil</creatorcontrib><creatorcontrib>Strauss, Louise</creatorcontrib><creatorcontrib>Galan, Gayle</creatorcontrib><creatorcontrib>Dixon, Lisa</creatorcontrib><creatorcontrib>McFadden, Christopher B.</creatorcontrib><creatorcontrib>Shoemaker, Laura</creatorcontrib><creatorcontrib>Gilbert, Ileen</creatorcontrib><creatorcontrib>Warren, Edward</creatorcontrib><creatorcontrib>Hammonds, Terry</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McFadden, E.R.</au><au>ElSanadi, Nabil</au><au>Strauss, Louise</au><au>Galan, Gayle</au><au>Dixon, Lisa</au><au>McFadden, Christopher B.</au><au>Shoemaker, Laura</au><au>Gilbert, Ileen</au><au>Warren, Edward</au><au>Hammonds, Terry</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Influence of Parasympatholytics on the Resolution of Acute Attacks of Asthma</atitle><jtitle>The American journal of medicine</jtitle><addtitle>Am J Med</addtitle><date>1997-01</date><risdate>1997</risdate><volume>102</volume><issue>1</issue><spage>7</spage><epage>13</epage><pages>7-13</pages><issn>0002-9343</issn><eissn>1555-7162</eissn><coden>AJMEAZ</coden><abstract>PURPOSE: To evaluate the role of parasympatholytics in the resolution of acute attacks of asthma.
METHODS: This study employed a prospective sequential design in which the influence of 0.5 and 1.0 mg of ipratropium bromide on peak expiratory flow rates (PEFR), hospital admissions, and length of stay (LOS) in the emergency department (ED) was evaluated. The parasympatholytic was added to a well-investigated standard therapeutic regimen that was anchored by the use of repetitive doses of albuterol, and employed pretested decision algorithms.
RESULTS: One hundred and thirty-one patients received ipratropium (I) and 123 who did not (NI) served as controls. There were no significant pretreatment between group differences in gender, racial composition, clinical signs and symptoms, or PEFR. The presence of ipratropium in the regimen did not influence discharge/admission patterns, LOS, the rate of improvement of the patients, or the level of PEFR achieved.
CONCLUSION: Anticholinergic agents such as ipratropium are not first-line treatments for acute asthma. They do not add any therapeutic benefit to the effects of albuterol given in divided doses over 1 hour, nor do they facilitate recovery in patients whose immediate response to sympathomimetics is impaired.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9209195</pmid><doi>10.1016/S0002-9343(96)00354-3</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9343 |
| ispartof | The American journal of medicine, 1997-01, Vol.102 (1), p.7-13 |
| issn | 0002-9343 1555-7162 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79100137 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Acute Disease Adult Albuterol - therapeutic use Asthma Asthma - drug therapy Asthma - physiopathology Biological and medical sciences Bronchodilator Agents - therapeutic use Drug therapy Female Hospitalization Humans Ipratropium - therapeutic use Length of Stay Male Medical research Medical sciences Parasympatholytics - therapeutic use Peak Expiratory Flow Rate - drug effects Pharmacology. Drug treatments Respiratory system Treatment Outcome |
| title | The Influence of Parasympatholytics on the Resolution of Acute Attacks of Asthma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A56%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Influence%20of%20Parasympatholytics%20on%20the%20Resolution%20of%20Acute%20Attacks%20of%20Asthma&rft.jtitle=The%20American%20journal%20of%20medicine&rft.au=McFadden,%20E.R.&rft.date=1997-01&rft.volume=102&rft.issue=1&rft.spage=7&rft.epage=13&rft.pages=7-13&rft.issn=0002-9343&rft.eissn=1555-7162&rft.coden=AJMEAZ&rft_id=info:doi/10.1016/S0002-9343(96)00354-3&rft_dat=%3Cproquest_cross%3E20861748%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=232355297&rft_id=info:pmid/9209195&rft_els_id=S0002934396003543&rfr_iscdi=true |